{
  "story_id": "f7549f33aa93919450754a94a6866d11",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-09-02T13:37:50.000Z",
  "content_hash": "0d9e79e0458620a688bdff49a42fd7b31843cd253f63aa5c9f8fb8c8a012edf0",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "UniQure NV stock gains 2.4% pre-market on William Blair Outperform initiation",
    "dek": "UniQure NV shares rose 2.4% in pre-market trading after William Blair initiated coverage with an Outperform rating.",
    "prose": "UniQure and the U.S. Food and Drug Administration (FDA) reached alignment in July 2026 on an accelerated Biologics License Application pathway for AMT-130, a gene therapy for Huntington's disease. [^1]\n\nWilliam Blair initiated coverage of UniQure NV (NASDAQ: QURE) with an 'Outperform' rating, which served as the immediate trigger for the stock's 2.4% pre-market gain. [^2]\n\nAccording to the article, analyst consensus on UniQure NV was 11 buy-equivalent ratings, 1 hold, and no sell recommendations. [^3]\n\nPresident Trump hailed new deals struck with biopharma companies this week as part of his commitment to lowering drug costs. [^4]\n\nSTAT's John Wilkerson writes that the new agreements could even undercut the administration's own efforts to lower drug costs. [^5]\n\nSTAT's John Wilkerson writes that the new agreements struck with biopharma companies may not amount to much in terms of lowering costs. [^6]\n\nUniQure stock traded below its 52-week high of $71.50 at the time of the article. [^7]\n\nUniQure submitted applications to the FDA and the UK's MHRA seeking marketing approval for AMT-130, its treatment for Huntington's disease. [^8]",
    "cited": "[{\"statement\":\"UniQure and the U.S. Food and Drug Administration (FDA) reached alignment in July 2026 on an accelerated Biologics License Application pathway for AMT-130, a gene therapy for Huntington's disease.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T12:12:40.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"William Blair initiated coverage of UniQure NV (NASDAQ: QURE) with an 'Outperform' rating, which served as the immediate trigger for the stock's 2.4% pre-market gain.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T12:12:40.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"According to the article, analyst consensus on UniQure NV was 11 buy-equivalent ratings, 1 hold, and no sell recommendations.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T12:12:40.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"President Trump hailed new deals struck with biopharma companies this week as part of his commitment to lowering drug costs.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T13:37:50.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"]},{\"statement\":\"STAT's John Wilkerson writes that the new agreements could even undercut the administration's own efforts to lower drug costs.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T13:37:50.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"]},{\"statement\":\"STAT's John Wilkerson writes that the new agreements struck with biopharma companies may not amount to much in terms of lowering costs.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T13:37:50.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"]},{\"statement\":\"UniQure stock traded below its 52-week high of $71.50 at the time of the article.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T12:12:40.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"UniQure submitted applications to the FDA and the UK's MHRA seeking marketing approval for AMT-130, its treatment for Huntington's disease.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T13:37:50.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"]}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": null,
  "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "bff47d2aa12d6bae23fd5ce4dd76be6c",
      "thread_id": "7013656202629c1bca0a7eed8e093de6",
      "thread_label": "AMT-130",
      "novelty": "UPDATE",
      "content_hash": "5f81eb3568f024cfe551379d55f8092f1115b928fce6be9c5fe1714c5e40b505",
      "last_published_at": "2026-09-02T13:37:50.000Z",
      "read_receipt": {
        "slice_hash": "48b2e0c3af4a8626da2fc811245788ff6e4271281efe8c00f25b0b05bb9edcc0",
        "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDJUMTM6MjE6NDUuMDAwMDAwWiIsImlkIjoiY2FjYjg1OTkyMDViN2I3MWM0YzhmYmUyYWMyZDA1OWYiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDJUMTM6NTU6MDUuMDAwMDAwWiIsImlkIjoiYWNhYmYyOWI5NzVlYzQwOTE2ZmQ0ODdhYWJiMGRmZGIiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 100,
        "window_days": 3,
        "bytes_scanned": 10113494,
        "credits": 8,
        "price_per_100_rows": 8,
        "sig": "1xwVD3uooFyxoSm6LPZf4A-bZFY74_s3o2sTcCuvLGZGzHvwRVCTx4NMLW2iH70kOvIw6hJoMKWNufYnsOQvDw",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      }
    },
    "written_at": "2026-09-03T00:31:36.191Z"
  },
  "cited_facts": [
    {
      "statement": "UniQure and the U.S. Food and Drug Administration (FDA) reached alignment in July 2026 on an accelerated Biologics License Application pathway for AMT-130, a gene therapy for Huntington's disease.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-02T12:12:40.000Z",
      "publisher_count": 1,
      "sources": [
        "Investing.com"
      ]
    },
    {
      "statement": "William Blair initiated coverage of UniQure NV (NASDAQ: QURE) with an 'Outperform' rating, which served as the immediate trigger for the stock's 2.4% pre-market gain.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-02T12:12:40.000Z",
      "publisher_count": 1,
      "sources": [
        "Investing.com"
      ]
    },
    {
      "statement": "According to the article, analyst consensus on UniQure NV was 11 buy-equivalent ratings, 1 hold, and no sell recommendations.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-02T12:12:40.000Z",
      "publisher_count": 1,
      "sources": [
        "Investing.com"
      ]
    },
    {
      "statement": "President Trump hailed new deals struck with biopharma companies this week as part of his commitment to lowering drug costs.",
      "source": "STAT",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-02T13:37:50.000Z",
      "publisher_count": 1,
      "sources": [
        "STAT"
      ]
    },
    {
      "statement": "STAT's John Wilkerson writes that the new agreements could even undercut the administration's own efforts to lower drug costs.",
      "source": "STAT",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-02T13:37:50.000Z",
      "publisher_count": 1,
      "sources": [
        "STAT"
      ]
    },
    {
      "statement": "STAT's John Wilkerson writes that the new agreements struck with biopharma companies may not amount to much in terms of lowering costs.",
      "source": "STAT",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-02T13:37:50.000Z",
      "publisher_count": 1,
      "sources": [
        "STAT"
      ]
    },
    {
      "statement": "UniQure stock traded below its 52-week high of $71.50 at the time of the article.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-02T12:12:40.000Z",
      "publisher_count": 1,
      "sources": [
        "Investing.com"
      ]
    },
    {
      "statement": "UniQure submitted applications to the FDA and the UK's MHRA seeking marketing approval for AMT-130, its treatment for Huntington's disease.",
      "source": "STAT",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-02T13:37:50.000Z",
      "publisher_count": 1,
      "sources": [
        "STAT"
      ]
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true."
}